2021-10-27-深交所-山河药辅_2021年第三季度报告_12页_274kb

Summary of Anhui SHENHE Pharmaceutical Additives Co., Ltd. 2021 Q3 Report

Financial Performance Overview

The company reported a strong revenue increase of 17.77% for the third quarter, reaching 446,238,820.02 yuan from the same period in 2020. Net profit grew by 6.11% to 72,541,670.80 yuan, while net profit after non-recurring items increased by 4.55% to 6,396,0742.23 yuan. Operating cash flow saw a significant rise of 137.68%, driven by increased sales.

Key Factors Influencing Results

Profit growth was moderated by rising raw material prices, exchange rate fluctuations, higher shipping costs, and production challenges due to power restrictions. Additional factors included increased expenses from new equity incentives. Subsidiary Curute Pharmaceutical Additives performed poorly due to high competition and cost pressures, leading to losses of -350,460,000 yuan in the first nine months, which partially offset the company's profits.

Balance Sheet Changes

Assets and equity increased slightly, with notable growth in accounts receivable (up 99.50% due to sales expansion) and intangible assets (up 51.4% from new land acquisitions). Liabilities remained stable, with operating cash flow improving significantly.

Shareholder Information

As of Q3 2021, key shareholders included Yin Zhenglong with 26.88% ownership and Shanghai Fosun Pharmaceutical Development with 11.19%. Total ordinary shareholders numbered 14,820, with concentrated holdings in major players.

Other Notes

No significant events or changes reported. The report is unaudited for the quarter.